Mirzaten Q-Tab (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2, 5‑HT3 and H1 receptors. This combined effect enhances serotonergic and noradrenergic transmission while providing sedative and anxiolytic benefits.

The appropriate dose of Mirzaten Q-Tab is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirtazapine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mirzaten Q-Tab.

To place an order, submit an enquiry on the Mirzaten Q-Tab product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in stronger sedative and appetite‑stimulating effects. This can be advantageous for patients with insomnia or weight loss, but may be less suitable for those who wish to avoid these side effects.

Mirzaten Q-Tab should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Mirzaten Q-Tab is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the potential for agranulocytosis, severe allergic reactions, and the emergence of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for any signs of infection, hypersensitivity, or worsening mood.

Individuals with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors, or patients with uncontrolled severe liver disease should avoid using Mirzaten Q-Tab. A healthcare professional should evaluate suitability for all other patients.